A detailed history of Bank Of America Corp transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Bank Of America Corp holds 430,782 shares of VKTX stock, worth $28.4 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
430,782
Previous 412,415 4.45%
Holding current value
$28.4 Million
Previous $33.8 Million 32.48%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$47.39 - $80.2 $870,412 - $1.47 Million
18,367 Added 4.45%
430,782 $22.8 Million
Q1 2024

May 15, 2024

SELL
$17.4 - $94.5 $6.23 Million - $33.9 Million
-358,208 Reduced 46.48%
412,415 $33.8 Million
Q4 2023

Feb 14, 2024

BUY
$9.24 - $19.64 $3.38 Million - $7.19 Million
365,857 Added 90.39%
770,623 $14.3 Million
Q2 2023

Aug 14, 2023

SELL
$14.84 - $24.79 $5.71 Million - $9.55 Million
-385,079 Reduced 48.75%
404,766 $6.56 Million
Q1 2023

May 12, 2023

BUY
$8.08 - $17.33 $5.6 Million - $12 Million
692,945 Added 715.11%
789,845 $13.2 Million
Q4 2022

Feb 10, 2023

SELL
$2.72 - $9.4 $56,793 - $196,272
-20,880 Reduced 17.73%
96,900 $910,000
Q3 2022

Nov 14, 2022

SELL
$2.55 - $3.89 $7,856 - $11,985
-3,081 Reduced 2.55%
117,780 $320,000
Q2 2022

Aug 12, 2022

BUY
$2.11 - $3.15 $148,328 - $221,438
70,298 Added 139.03%
120,861 $349,000
Q1 2022

May 16, 2022

SELL
$3.0 - $4.88 $12,174 - $19,803
-4,058 Reduced 7.43%
50,563 $152,000
Q4 2021

Feb 08, 2022

SELL
$4.6 - $6.72 $1.09 Million - $1.6 Million
-237,961 Reduced 81.33%
54,621 $251,000
Q3 2021

Nov 15, 2021

BUY
$5.58 - $7.04 $82,801 - $104,466
14,839 Added 5.34%
292,582 $1.84 Million
Q2 2021

Sep 13, 2021

BUY
$5.19 - $6.73 $1.44 Million - $1.87 Million
277,743 New
277,743 $1.66 Million

Others Institutions Holding VKTX

About Viking Therapeutics, Inc.


  • Ticker VKTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,688,496
  • Market Cap $5.05B
  • Description
  • Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...
More about VKTX
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.